98%
921
2 minutes
20
Oral carcinoma (OC) is a toxic illness among the most general malignant cancers globally, and it has developed a gradually significant public health concern in emerging and low-to-middle-income states. Late diagnosis, high incidence, and inadequate treatment strategies remain substantial challenges. Analysis at an initial phase is significant for good treatment, prediction, and existence. Despite the current growth in the perception of molecular devices, late analysis and methods near precision medicine for OC patients remain a challenge. A machine learning (ML) model was employed to improve early detection in medicine, aiming to reduce cancer-specific mortality and disease progression. Recent advancements in this approach have significantly enhanced the extraction and diagnosis of critical information from medical images. This paper presents a Deep Structured Learning with Vision Intelligence for Oral Carcinoma Lesion Segmentation and Classification (DSLVI-OCLSC) model for medical imaging. Using medical imaging, the DSLVI-OCLSC model aims to enhance OC's classification and recognition outcomes. To accomplish this, the DSLVI-OCLSC model utilizes wiener filtering (WF) as a pre-processing technique to eliminate the noise. In addition, the ShuffleNetV2 method is used for the group of higher-level deep features from an input image. The convolutional bidirectional long short-term memory network with a multi-head attention mechanism (MA-CNN-BiLSTM) approach is utilized for oral carcinoma recognition and identification. Moreover, the Unet3 + is employed to segment abnormal regions from the classified images. Finally, the sine cosine algorithm (SCA) approach is utilized to hyperparameter-tune the DL model. A wide range of simulations is implemented to ensure the enhanced performance of the DSLVI-OCLSC method under the OC images dataset. The experimental analysis of the DSLVI-OCLSC method portrayed a superior accuracy value of 98.47% over recent approaches.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11850820 | PMC |
http://dx.doi.org/10.1038/s41598-025-89971-5 | DOI Listing |
Periodontol 2000
September 2025
Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Oral cancer is a major global health burden, ranking sixth in prevalence, with oral squamous cell carcinoma (OSCC) being the most common type. Importantly, OSCC is often diagnosed at late stages, underscoring the need for innovative methods for early detection. The oral microbiome, an active microbial community within the oral cavity, holds promise as a biomarker for the prediction and progression of cancer.
View Article and Find Full Text PDFBr J Oral Maxillofac Surg
August 2025
Department of Oral and Maxillofacial Surgery, Manipal College of Dental Sciences, Mangalore, Manipal Academy of Higher Education, Manipal 576104, India. Electronic address:
Intern Med
September 2025
Department of Gastroenterology and Hepatology, Toyota Kosei Hospital, Japan.
Agranulocytosis is an extremely rare but potentially fatal immune-related adverse event (irAE) induced by immune checkpoint inhibitors (ICIs). Its management, particularly following combination therapies such as durvalumab/tremelimumab (Dur/Tre) for hepatocellular carcinoma (HCC), is challenging owing to limited data. We herein report a 79-year-old man with HCC who developed severe Dur/Tre-induced agranulocytosis that was refractory to granulocyte colony-stimulating factor, high-dose corticosteroids, and intravenous immunoglobulin.
View Article and Find Full Text PDFBMJ Open
September 2025
Department of Gastroenterology, Hepatology, Infectious Diseases and Intoxication, University Hospital Heidelberg, Heidelberg, Germany.
Introduction: Combined vascular endothelial growth factor/programmed death-ligand 1 blockade through atezolizumab/bevacizumab (A/B) is the current standard of care in advanced hepatocellular carcinoma (HCC). A/B substantially improved objective response rates compared with tyrosine kinase inhibitor sorafenib; however, a majority of patients will still not respond to A/B. Strong scientific rationale and emerging clinical data suggest that faecal microbiota transfer (FMT) may improve antitumour immune response on PD-(L)1 blockade.
View Article and Find Full Text PDF